Position effects due to disruption of distant cis-regulatory regions have been reported for over 40 human gene loci; however, the underlying mechanisms of long-range gene regulation remain largely unknown. We report two patients with Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) caused by overlapping genomic deletions that included a distant FOXF1 transcriptional enhancer mapping 0.3 Mb upstream to FOXF1 on 16q24.1. In one patient with atypical late-onset ACDMPV, a ~ 1.5 Mb deletion removed the proximal 43% of this enhancer, leaving the lung-specific long non-coding RNA (lncRNA) gene LINC01081 intact. In the second patient with severe neonatal-onset ACDMPV, an overlapping ~ 194 kb deletion disrupted LINC01081. Both deletions arose de novo on maternal copy of the chromosome 16, supporting the notion that FOXF1 is paternally imprinted in the human lungs. RNAi-mediated knock-down of LINC01081 in normal fetal lung fibroblasts showed that this lncRNA positively regulates FOXF1 transcript level, further indicating that decrease in LINC01081 expression can contribute to development of ACDMPV.
Introduction
Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) (OMIM 265380) is a rare, lethal disorder of the lungs. Affected patients typically present with severe respiratory failure and refractory pulmonary hypertension within a few hours after birth and die in the first month of life, although rare late-onset presentations have been reported [Abdallah et al., 1993; Licht et al., 2004; Shankar et al., 2006; Ahmed et al., 2008] . Histopathologically, ACDMPV is characterized by malposition of pulmonary veins adjacent to small pulmonary arteries, medial thickening of small pulmonary arteries, deficient lobular development, a paucity of alveolar wall capillaries, and occasional lymphangiectasis [Langston 1991] . The majority of patients with ACDMPV also have extra-pulmonary anomalies of the gastrointestinal, cardiovascular, and genitourinary systems [Sen et al., 2004; Bishop et al., 2011] .
Heterozygous point mutations or genomic deletions of FOXF1 (MIM 601089) have been reported in most patients with ACDMPV [Stankiewicz et al., 2009; Sen et al., 2013a,b; Szafranski et al., 2013a] . Recently, we have defined a ~ 75 kb differentially methylated and evolutionarily conserved cis-regulatory region mapping to a protein-coding gene desert 2 57 kb upstream to FOXF1 and functioning as its tissue-specific enhancer [Szafranski et al., 2013b] . This region harbors, among others, genes for fetal lung-enriched long non-protein coding RNAs (lncRNAs), transcription factor GLI2-binding sites, and the differentiallymethylated CpG island, likely contributing to the paternal genomic imprinting of the FOXF1 in the human lungs [Sen et al., 2013a,b; Szafranski et al., 2013a] . lncRNAs are the least understood elements of the FOXF1 distant enhancer. These RNAs are broadly classified as 5′-capped and polyadenylated transcripts longer than 100-200 nucleotides (nt) (as opposed to 21-35-nt miRNAs and other small RNAs), and exhibiting very limited protein-coding potential [Yang et al., 2014] . More than 1/3 of the already studied lncRNAs associate with chromatin modifying complexes and target them to specific genomic regions [Khalil et al., 2009] . Others function as decoys for transcription regulators and miRNAs, as suppliers of transcription factor and repressor complexes for promoters, or can be directly involved in posttranscriptional regulation of mRNA processing, and translation [Yang et al., 2014] .
Here, we show that partial deletion of the distant FOXF1 enhancer that leaves the lncRNA LINC01081 intact, was associated with a late-onset ACDMPV phenotype, whereas an overlapping deletion that disrupted the LINC01081 gene resulted in a neonatal-onset, classic ACDMPV phenotype. We verified the role of LINC01081 in regulation of the FOXF1 expression and etiology of ACDMPV by RNAi-based FOXF1 knock-down in fetal lung fibroblasts.
Material and Methods

DNA and RNA isolation, DNA sequencing and sequence analysis
Blood and lung samples were obtained after informed consents. DNA was extracted from peripheral blood, and RNA was extracted from FFPE ACDMPV lung tissue, frozen normal lung tissue, and normal human fetal lung fibroblasts MRC-5 and IMR-90 (ATCC) as described [Szafranski et al. 2013a,b] . PCR products were directly sequenced by the Sanger method. Reference sequences were downloaded from the UCSC Genome Browser (NCBI build 37/hg19, http://genome.ucsc.edu). Sequences were assembled using Sequencher v4.8 (GeneCodes).
Array CGH and deletion analysis
Genomic copy-number variants (CNVs) were analyzed using array CGH with customdesigned 16q24.1 region-specific 3x720K microarrays (Roche NimbleGen) (patient 99.3) and 4x180K microarrays (Agilent) (patient 111.3) according to manufacturer's protocols. Amplification of a junction fragment for sequencing was performed using LA Taq polymerase (TaKaRa Bio USA) as described [Szafranski et al. 2013a,b] . Parental origin of the deletion was determined following identification of an informative SNP and a microsatellite polymorphism in parental and patient's chromosomes.
Real time quantitative PCR analysis of the FOXF1 transcript
RNA samples from control and ACDMPV lungs and from cultured normal fetal lung fibroblasts were reverse-transcribed using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). TaqMan primers and probes were synthesized by Applied Biosystems. Primers for FOXF1 were: 5′-CGAGCTGCAAGGCATCCCGCGGTAT-3′ and 5′-CAAGAGGAAGAGAGAGACCCTCACT-3′. FOXF1 transcript levels were normalized to GAPDH. qPCR was repeated four times using TaqMan Universal PCR Master Mix (Applied Biosystems). qPCR conditions included 40 cycles of 95°C for 15 s and 60°C for 1 min. For relative quantification of the FOXF1 transcript, the comparative ΔC T method was used. Normal fetal lung was designated as a calibrator sample.
siRNA knock-down of lncRNAs
Knock-down experiments with RNAi were performed using two custom-designed (Ambion) Silencer Select siRNA doublets per knock-down (Table S1 -see supporting information online). IMR-90 cells were maintained in the Eagle's minimum essential medium (EMEM) supplemented with 2 mM L-glutamine and 10% FBS (ATCC). For siRNA transfection, cells were treated with Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocol. 4.5 μl of Lipofectamine per well in 12-well plate format was applied. The final concentration of each siRNA was 15 nM. RNA was prepared from cultured cells 48 hrs after transfection.
Clinical Report Patient 1
Patient 1 (99.3) was a full term 4.57 kg female infant born to a 29-year-old gravida 2 para 2 mother, whose pregnancy was complicated by type I diabetes. Shortly after birth, the infant developed respiratory distress with tachypnea and retractions. Over the next six months, she had marginal weight gain and persistent subcostal retractions. At seven months of age she developed acute respiratory distress and fever while vacationing with her family at high altitude. Her examination was significant for severe subcostal retractions, hypoxemia (oxygen saturations of 86-93% while breathing room air), and tachypnea. Chest radiograph demonstrated scattered interstitial opacities (Fig. 1A ) and her chest lung CT showed diffuse, bilateral ground-glass infiltrates with extensive septal line thickening and scattered areas of mosaic attenuation. Her echocardiogram demonstrated evidence of significant pulmonary hypertension, and she was commenced on inhaled nitric oxide and oral sildenafil. A lung biopsy showed misalignment of the pulmonary veins, diffuse smooth muscle hyperplasia of arteries and arterioles, and focal areas of centrally located capillaries within widened alveolar septa. She clinically stabilized and did relatively well until 14 months of age when she developed severe hypoxic respiratory failure due to viral respiratory infection and required extracorporeal membrane oxygenation (ECMO). She underwent orthotopic bilateral lung transplantation at 15 months of age. Her explanted lung showed scattered misaligned veins within bronchovascular bundles in all lobes, central placement of capillaries within widened alveolar septa in peripheral areas of all lobes, diffuse medial wall thickening of arteries and arterioles, and marked lymphangiectasia in interlobular septa and around bronchovascular bundles (Fig. 1B, C) .
Patient 2
Patient 2 (111.3) was a full-term male infant presenting with cyanosis and hypoxemia (50%) at a few hours of life and required intubation. Echocardiogram demonstrated severe pulmonary hypertension with exclusive right to left shunting through his patent ductus arteriosus and dilated right ventricle with depressed function. He had no clinical response to inhaled nitric oxide and trepostinil and was placed on ECMO for refractory respiratory failure. He continued to demonstrate severe pulmonary hypertension. Lung biopsy at 11 days of age confirmed the clinical suspicion of ACDMPV (Fig. 1D) . Due to the poor prognosis, ECMO was discontinued, and he died at 13 days of life. Lungs at autopsy demonstrated the features of ACDMPV with diffuse misalignment of pulmonary veins.
Results
Histopathological analysis of lung biopsy and explant in patient 99.3 showed characteristic findings of ACDMPV (Fig. 1B, C ). While this patient had persistent respiratory symptoms that began in the newborn period, she did not develop respiratory failure until after a year of life, consistent with atypical ACDMPV. Her late presentation correlated with pathological features of the explanted lung, which demonstrated scattered misaligned veins. Lung biopsy in patient 111.3 showed the typical ACDMPV features with diffusely misaligned veins (Fig.  1D) .
In both cases, DNA sequencing did not find any evidence of point mutation in FOXF1. Array CGH analyses revealed two overlapping deletions on 16q24.1 leaving FOXF1 intact: a ~ 1.5 Mb deletion mapping ~ 306 kb upstream to FOXF1 in patient 99.3 and a ~ 194 kb deletion located ~ 272 kb upstream to FOXF1 in patient 111.3 ( Fig. 2A) . In patient 99.3 with an atypical ACDMPV presentation, the deletion removed 26 kb of the proximal portion (chr16: 86,212,040-86,238,601/86,238,621) chr16:86,212,040-86,287,054) , but left the lung-specific lncRNA gene LINC01081 intact (Fig. 2B) . In patient 111.3 with severe ACDMPV, the deletion extended to chr16:86,271,915/86,271,919, and disrupted LINC01081, thus narrowing the enhancer region to ~ 60 kb (chr16:86,212,040-86,271,915/86,271,919) (Fig. 2B) .
Real-time qPCR analysis of RNA isolated from the FFPE lung tissue from patient 99.3 demonstrated a significant (70%) reduction of FOXF1 expression when compared with that in normal lungs (Fig. 3) . However, since only a single FFPE specimen was available for analysis, we could not estimate mean expression of FOXF1 in her lungs for comparison with FOXF1 transcript levels in a severe ACDMPV cases .
To infer the molecular mechanisms of deletion formation and to assess recurrence risk, we sequenced the breakpoints of both deletions. In patient 99.3, both deletion breakpoints mapped within the Alu repetitive elements; the proximal breakpoint mapped within AluSc8 between 84,764,627 and 84,764,647, and the distal breakpoint within AluY between 86,238,601 and 86,238,621 (Fig. 4A) . The proximal breakpoint of the deletion in patient 111.3 mapped within LTR ERVL, between 86,077,954 and 86,077,958 and the distal breakpoint mapped within LINE L1 element, between 86,271,915 and 86,271,919 (Fig. 4A) . In both deletions, the breakpoints were associated with the presence of 19 bp (99.3) and 3 bp (111.3) microhomologies, suggesting they might have arisen by a template switching replicative mechanism such as fork stalling and template switching (FoSTeS) or microhomology-mediated break-induced replication (MMBIR) [Lee et al., 2007; Hastings et al., 2009] . Of interest, three of the four breakpoints were adjacent to DNA regions with locally increased GC content (data not shown).
Consistent with the accumulating evidence that suggests partial paternal imprinting of the FOXF1 locus [Stankiewicz et al. 2009; Sen et al., 2013b; Szafranski et al., 2013a ,b], we found that both deletions arose de novo on the maternal chromosome 16 (Fig. 4B) . We did not find any evidence for low-level somatic mosaicism in either of the maternal DNA samples using PCR for patient-specific junction fragments (Fig. 4C) .
To experimentally verify the involvement of LINC01081 in regulation of FOXF1 expression and etiology of ACDMPV, we reduced the levels of lncRNAs LINC01081 and TCONS_00024781 (a lung-enriched stand-alone lncRNA encoded in chr16q24.1, but not within any of the deleted regions) using RNAi in normal fetal lung fibroblasts, and quantified FOXF1 expression by RT qPCR. We found that targeting LINC01081 with two different pairs of siRNAs reduced FOXF1 transcript levels by 14 and 20%, whereas decreasing the expression of TCONS_00024781 did not affect the FOXF1 expression (Fig.  5) . Thus, we conclude that LINC01081 positively and specifically regulates FOXF1 expression. The discordance in phenotypes between our patients suggests that regulation of FOXF1 expression by LINC01081 contributes to onset of ACDMPV symptoms.
Discussion
Recently, we characterized an ~ 75 kb FOXF1 transcriptional enhancer defined by nine overlapping deletions. It maps ~ 257 kb upstream to FOXF1, includes two conserved segments that exhibit high regulatory potential, and encodes differentially-spliced lungspecific lncRNAs [Szafranski et al., 2013] . Deletion of the entire enhancer or its mislocalization (e.g. due to balanced inversion) resulted in the neonatal onset classic ACDMPV phenotype [Stankiewicz et al., 2009; Szafranski et al., 2013a; Parris et al., 2013] . Genotype-phenotype correlations in patient (99.3) with atypical ACDMPV and in patient (111.3) with severe early-onset ACDMPV enabled us to further narrow this enhancer region. Array CGH analyses revealed overlapping deletions at chr16q24.1 that removed 35% (patient 99.3) and 80% (patient 111.3) of the ~ 75 kb FOXF1 enhancer region.
The vast majority of children with ACDMPV die, like patient 111.3, within the first month of life; longer survivals and later presentations have been rarely reported [Abdallah et al., 1993; Licht et al., 2004; Shankar et al., 2006; Ahmed et al., 2008] . Patient 99.3 had mild respiratory symptoms at birth and survived 15 months before undergoing lung transplantation and was one of the oldest known patient with atypical presentation of ACDMPV. Whereas her lung biopsy and explant showed the hallmark features of ACDMPV, there was non-uniform distribution of misaligned veins in the bronchovascular bundles compared to that typically observed in patients with severe full ACDMPV phenotype.
Correlation analysis of the deletions and their associated lung phenotypes in our two patients indicated that: (i) removal of one of the two segments of this enhancer region, Segment 1, that contains GLI2-binding sites, partially overlapping differentially methylated CpG island, and a lncRNA gene LINC01082, results in a milder atypical form of ACDMPV with focal pulmonary vein misalignment, and that (ii) decrease of the lung-specific lncRNA LINC01081, partially encoded by the Segment 2 of the enhancer and disrupted in patient 111.3 (in addition to the loss of the Segment 1) contributes to severity of ACDMPV likely by decreasing FOXF1 expression. Late onset of ACDMPV and scattered interstitial opacities in the lungs in patient 1 could be also explained by lung somatic mosaicism that was not detectable in the blood. Using RNAi, we decreased the levels of LINC01081 in normal fetal lung fibroblasts, demonstrating that indeed LINC01081 regulates expression of FOXF1.
The molecular mechanisms of positive regulation of gene expression by lncRNAs are only starting to emerge [Tsai et al., 2010; Ørom et al., 2014] . We speculate that LINC01081 may control FOXF1 expression through modification of chromatin architecture around the FOXF1 promoter, by supplying the promoter with transcription factors, or by providing the decoy targets for miRNAs or transcription inhibitors. Using qPCR, we also showed that deletion of Segment 1 in patient 99.3 correlates with decrease of FOXF1 transcript, independently indicating that this enhancer indeed controls expression of FOXF1 in vivo. It would be interesting to study the phenotypic effects of knock-down of the other lincRNA LINC01082.
Of interest, both de novo deletions arose on maternal copy of chromosome 16, similarly to other 16 previously analyzed FOXF1 locus deletions in patients with ACDMPV, further supporting the notion that FOXF1 is paternally imprinted in the human lungs, although incompletely [Stankiewicz et al. 2009; Szafranski et al. 2103a; Sen et al. 2013a ].
In summary, (i) we narrowed the regulatory region located ~ 272 kb upstream to FOXF1 tõ 60 kb and showed that its loss correlated with FOXF1 expression in vivo, (ii) demonstrated that lncRNA LINC01081, encoded in the distal portion of this enhancer (Segment 2), positively regulated FOXF1 transcript level and its disruption can contribute to the development of the classic neonatal-onset ACDMPV phenotype, and (iii) provide data indicating that the removal of the proximal portion of the enhancer (Segment 1), containing GLI2-binding sites and lncRNA LINC01082, but leaving LINC01081 intact, can result in atypical ACDMPV.
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